Zentalis Pharmaceuticals (ZNTL) Other Non Operating Income (2021)

Zentalis Pharmaceuticals' (ZNTL) quarterly Other Non Operating Income came in at $51.6 million in Q3 2021.

Zentalis Pharmaceuticals (ZNTL) Other Non Operating Income (2021) Analysis & Trends

Zentalis Pharmaceuticals' Other Non Operating Income history runs 1 years deep, the most recent figure standing at $51.6 million for Q3 2021.

On a quarterly basis, Other Non Operating Income changed N/A year-over-year to $51.6 million in Q3 2021; TTM through Dec 2022 was $51.6 million, a 0.0% change from a year earlier, with the FY2021 full-year figure at $51.6 million, changed N/A from the prior year.
Other Non Operating Income steadied at $51.6 million in Q3 2021 per ZNTL's latest filing.
Across five years, Other Non Operating Income topped out at $51.6 million in Q3 2021 and bottomed at $51.6 million in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Zentalis Pharmaceuticals	312.67 Mn	312.67 Mn	-

Download Data

Date	Value
Sep 30, 2021	51.58 Mn